Target Discovery Institute, NDM Research Building, Old Road Campus, Headington, Oxford, United Kingdom.
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Mol Cancer Ther. 2019 Feb;18(2):376-388. doi: 10.1158/1535-7163.MCT-17-0857. Epub 2018 Nov 26.
Tumor cells exhibit altered lipid metabolism compared with normal cells. Cell signaling kinases are important for regulating lipid synthesis and energy storage. How upstream kinases regulate lipid content, versus direct targeting of lipid-metabolizing enzymes, is currently unexplored. We evaluated intracellular lipid concentrations in prostate and breast tumor spheroids, treated with drugs directly inhibiting metabolic enzymes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), diacylglyceride acyltransferase (DGAT), and pyruvate dehydrogenase kinase (PDHK), or cell signaling kinase enzymes PI3K, AKT, and mTOR with lipidomic analysis. We assessed whether baseline lipid profiles corresponded to inhibitors' effectiveness in modulating lipid profiles in three-dimensional (3D) growth and their relationship to therapeutic activity. Inhibitors against PI3K, AKT, and mTOR significantly inhibited MDA-MB-468 and PC3 cell growth in two-dimensional (2D) and 3D spheroid growth, while moderately altering lipid content. Conversely, metabolism inhibitors against FASN and DGAT altered lipid content most effectively, while only moderately inhibiting growth compared with kinase inhibitors. The FASN and ACC inhibitors' effectiveness in MDA-MB-468, versus PC3, suggested the former depended more on synthesis, whereas the latter may salvage lipids. Although baseline lipid profiles did not predict growth effects, lipid changes on therapy matched the growth effects of FASN and DGAT inhibitors. Several phospholipids, including phosphatidylcholine, were also upregulated following treatment, possibly via the Kennedy pathway. As this promotes tumor growth, combination studies should include drugs targeting it. Two-dimensional drug screening may miss important metabolism inhibitors or underestimate their potency. Clinical studies should consider serial measurements of tumor lipids to prove target modulation. Pretherapy tumor classification by lipid synthesis versus uptake may help demonstrate efficacy.
与正常细胞相比,肿瘤细胞表现出改变的脂质代谢。细胞信号转导激酶对于调节脂质合成和能量储存非常重要。目前尚不清楚上游激酶如何调节脂质含量,与直接靶向脂质代谢酶相比。我们使用脂质组学分析评估了用直接抑制代谢酶脂肪酸合酶(FASN)、乙酰辅酶 A 羧化酶(ACC)、二酰基甘油酰基转移酶(DGAT)和丙酮酸脱氢酶激酶(PDHK)的药物以及细胞信号转导激酶酶 PI3K、AKT 和 mTOR 处理的前列腺和乳腺癌肿瘤球体中的细胞内脂质浓度。我们评估了基线脂质谱是否与抑制剂在调节三维(3D)生长中的脂质谱的有效性相对应,以及它们与治疗活性的关系。针对 PI3K、AKT 和 mTOR 的抑制剂在二维(2D)和 3D 球体生长中显著抑制了 MDA-MB-468 和 PC3 细胞的生长,同时适度改变了脂质含量。相反,针对 FASN 和 DGAT 的代谢抑制剂最有效地改变了脂质含量,而与激酶抑制剂相比,生长抑制作用仅中等。FASN 和 ACC 抑制剂在 MDA-MB-468 中的有效性,与 PC3 相比,前者可能更多地依赖于合成,而后者可能会挽救脂质。尽管基线脂质谱不能预测生长效果,但治疗中的脂质变化与 FASN 和 DGAT 抑制剂的生长效果相匹配。几种磷脂,包括磷脂酰胆碱,在治疗后也被上调,可能通过 Kennedy 途径。由于这促进了肿瘤的生长,联合研究应该包括针对它的药物。二维药物筛选可能会错过重要的代谢抑制剂或低估其效力。临床研究应考虑对肿瘤脂质进行连续测量以证明靶标调节。治疗前通过脂质合成与摄取对肿瘤进行分类可能有助于证明疗效。